Open Orphan wins new £4.3m challenge study deal
Dublin-listed pharmaceutical company Open Orphan has announced a new £4.3m contract to conduct a human viral challenge study using one of its eight traditional challenge study models for another of the global top 10 vaccine companies.
Business
• 28 Sep 20
